Skip to content
Search

Latest Stories

Boots and PDA Union reach agreement in pay talks

Boots and PDA Union reach agreement in pay talks

All eligible pharmacists and pharmacist store managers at Boots will receive a 4% pay increase

Boots and the PDA Union negotiating teams have reached an agreement on this year’s pay claim, following constructive negotiations between both parties. The new pay deal will come into effect from 1 November 2024.

Under the agreement, all eligible pharmacists and pharmacist store managers within the bargaining unit will receive a 4 per cent pay award, recognising their unique role within the community pharmacy sector and the business.


Pharmacists and pharmacist store managers will qualify for the negotiated rates if they are members of the bargaining unit, employed as of 1 November 2024, and not serving a notice period.

However, the pay award will not apply to those who have joined or had a pay increase on or since 1 August 2024, were rated as not performing at EOY 2024, or are a trainee pharmacist.

All qualified pharmacists in the bargaining unit with over 10 years of service at Boots will receive a minimum of £53,000 FTE per annum, while all substantively appointed and performing Boots Pharmacist Store Managers will be paid a minimum of £55,000 FTE per annum.

If any eligible pharmacists or pharmacist store managers remain below this minimum threshold after receiving the 4 per cent pay increase, they will receive an additional adjustment to ensure their salary meets this level. This adjustment will also take effect from 1 November 2024.

Boots has also agreed to increase the honorarium payment for pharmacists supporting trainee pharmacists from £1,000 to £1,500 as a non-consolidated payment.

Eligible pharmacists supporting trainee pharmacists from the 2024/25 cohort onwards will receive the revised payment after the 52-week sign-off is completed, with the amount pro-rated as usual.

Additionally, it has been agreed that the current Short Notice Payments provision and eligibility criteria will continue as last year.

 

 

More For You

NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
AAH upgrades ordering portal, making procurement easier for pharmacies

AAH Cascade compares prices and availability across suppliers

AAH Warehouse

AAH upgrades ordering portal to improve product visibility

Leading pharmaceutical wholesaler AAH Pharmaceuticals Ltd has introduced new digital functionalities to AAH Cascade, its independently managed ordering portal, making procurement easier and more cost-effective for pharmacies.

AAH Cascade compares product prices and availability across multiple suppliers, eliminating the need for manual searches.

Keep ReadingShow less
Majority of Brits neglect consistent skincare routine,  survey finds

On average, Brits go to bed without washing their face twice a week.

Photo credit: gettyimages

Skincare: One in five Brits go to bed without washing their face daily, survey finds

Nearly two-thirds of Brits (60 per cent) neglect a consistent skincare routine,with almost one in five going to bed without washing their face daily, according to a new survey by consumer health company Kenvue.

The UK-wide survey of 2,000 people revealed that one-third of respondents (34 per cent) spend five minutes or less on their daily skincare routine. On average, Brits go to bed without washing their face twice a week.

Keep ReadingShow less
Risk of pharmacy closures remains despite record funding uplift

Community pharmacy sector remains in a fragile position as the funding gap is still significant, says CCA.

gettyimages

Pharmacy closures still a risk as funding deal fails to cover costs – warns CCA

The community pharmacy sector has secured the largest funding uplift across the NHS, yet concerns remain that it may not be enough to prevent further closures and service reductions.

Following a six-week consultation with Community Pharmacy England (CPE), the government has approved a £3.073 billion funding package for 2025/26, supplemented by an additional £215 million to support Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less